December 2012- Volume 8, Issue 12

December 2012

In this Issue

Research & Development

Neurodegeneration dream team

Neurodegeneration dream team

$25 million gift funds ambitious group of experts on quest to unlock Alzheimer’s and other diseases

Give me a ‘C’

Give me a ‘C’

GSK, Vertex Pharmaceuticals to conduct Phase II hepatitis C studies

Macrocycles by the millions

Macrocycles by the millions

Ensemble Therapeutics and Boehringer Ingelheim collaborate on macrocycle drug candidates for BI targets

Forest, Adamas announce licensing agreement for dementia therapy

Forest, Adamas announce licensing agreement for dementia therapy

Forest Laboratories Inc. and Adamas Pharmaceuticals Inc. have announced the signing of a licensing agreement

Lots of attention for ADHD

Lots of attention for ADHD

Pfizer acquires NextWave Pharmaceuticals, gains ADHD compounds in deal worth up to $700 million

Amgen, KPCB create new spinout biotech firm

Amgen, KPCB create new spinout biotech firm

Atara Biotherapeutics will focus on cancer, kidney disease

Global News

A harmonious position

A harmonious position

France’s Curie-Cancer, Harmonic Pharma form research collaboration to explore molecular repositioning in fight against cancer

OBT, easy as ADC

OBT, easy as ADC

Oxford BioTherapeutics and Menarini Group co-develop antibody-based cancer drugs

A multinational merger

A multinational merger

EpiCept-Immune Pharma union weds two biopharmaceutical companies with complementary portfolios and facilities

Trio is together again

Trio is together again

Strategic drug discovery alliance between Astex Pharmaceuticals, Cancer Research Technology and Newcastle University builds on long-term relationship

Omics & Systems Biology

Paving the way to personalized medicine

Paving the way to personalized medicine

Foundation Medicine and AstraZeneca collaborate to identify genomic predictors for cancer therapy response

Tennessee titans (of healthcare)

Tennessee titans (of healthcare)

Mid-South healthcare powerhouses join forces to advance personalized medicine and improve access to sophisticated care

GENESIS of gene editing

GENESIS of gene editing

Horizon Discovery and UCL Institute of Neurology collaborate in rAAV-mediated genome editing

bacTRAP, do it again

bacTRAP, do it again

Takeda subsidiary acquires longtime collaborator Envoy Therapeutics for $140 million

An ‘almost perfect match’

An ‘almost perfect match’

Red Glead, SARomics pursue epigenetics partnership

Feature

SLAS2013 preview: Inside inspiration (part 2)

SLAS2013 preview: Inside inspiration (part 2)

Member input and needs strong driver for second annual SLAS meeting

SLAS2013 preview: Inside inspiration (part 1)

SLAS2013 preview: Inside inspiration (part 1)

Member input and needs strong driver for second annual SLAS meeting

Contract Services

Where two Rivers meet

Where two Rivers meet

Charles River gains majority ownership of research model provider Vital River

A la carte

A la carte

French CRO Biotrial buys Bioanalytical Services division of Warnex

Anticancer stem cell therapeutics

Anticancer stem cell therapeutics

Lonza and OncoMed Pharmaceuticals will collaborate on process development and manufacturing of multiple products

Fujifilm, Piramal simplify complexities

Fujifilm, Piramal simplify complexities

Fujifilm Diosynth Biotechnologies and Piramal Healthcare pair up to produce ADCs through a simpler supply chain

Oxygen Biotherapeutics engages PPD to execute trial for brain injury therapy

Oxygen Biotherapeutics engages PPD to execute trial for brain injury therapy

Oxygen Biotherapeutics Inc. recently announced that it has tapped Pharmaceutical Product Development LLC (PPD) to resume and complete OBI’s STOP-TBI Phase II-b clinical trial

Diagnostics

QIAGEN for CDx

QIAGEN for CDx

QIAGEN and Bayer HealthCare partner to develop companion diagnostics for targeted cancer therapies

IRIS opens on diagnostics

IRIS opens on diagnostics

Danaher subsidiary acquires diagnostic systems developer IRIS International for $338 million, adding it under Beckman Coulter umbrella

Vive la France

Vive la France

Paris-based Exonhit merges with InGen BioSciences; creating in-vitro diagnostics company

Gaining ground on multiple sclerosis

Gaining ground on multiple sclerosis

Ezose Sciences forms alliance with Fast Forward to discover biomarkers for diagnosing multiple sclerosis

Marked for survival

Marked for survival

Skuldtech and AB Science discover masitinib-associated predictive markers for pancreatic cancer survival

Tools & Technology

Room for IMPROVER

Room for IMPROVER

IBM and Philip Morris team up to create verification process for systems biology data

Life Tech acquires Advanced Microscopy Group

Life Tech acquires Advanced Microscopy Group

Acquisition establishes foundation for new product innovation in fluorescent and brightfield imaging devices

Hide and BioSeek

Hide and BioSeek

DiscoveRx finds phenotypic screening solutions in new acquisition

Bottom-up ‘omics integration

Bottom-up ‘omics integration

Agilent, Spain’s Centre for Omic Sciences in systems biology collaboration

Editor's Focus

A reflection on the old and in with the new

A reflection on the old and in with the new

There’s a facelift for ddn beginning in December, and some new directions for coverage going into 2013. With regard to that and more, the magazine’s chief editor, Amy Swinderman, walks you through some of the highlights of the past year and what’s in store for the future

Commentary

I’ve fallen … and I can’t get up!

I’ve fallen … and I can’t get up!

Some say there is no room for politics in science. That’s wrong. Politics is what distinguishes us from raccoons and is what funds science and medicine, like it or not

An alternative view of drug-like properties

An alternative view of drug-like properties

The terms “drug-like” and “drug-like properties” have gained common currency in the drug discovery community. They usually refer to the values of simple physicochemical and structural compound properties that successful drugs have in common. However, despite the frequency with which these terms are used, “drug-like” means different things to different people and will depend on a project’s specific objective
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022